



Alzinova terminates agreement with liquidity provider

Alzinova AB ("Alzinova" or "the Company") has terminated the agreement with Mangold Fondkommission AB ("Mangold") on the assignment as liquidity provider. The last day for liquidity support trading by Mangold is 28 April 2023.

The purpose of the liquidity provider has been to promote liquidity in the Company's share and reduce volatility and thus facilitate trading. The liquidity in the share is sufficient, and management therefore considers that the need for a liquidity provider no longer exists.

For more information, please contact:

Kristina Torfgård, CEO

Tel. +46 708 46 79 75

E-mail: kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A β CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com



Attachments

Alzinova terminates agreement with liquidity provider